PetMed Express, Inc. (PETS)
USD 5.28
(-5.38%)
USD 5.28
(-5.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -394 Thousand USD | -152.27% |
| 2023 | 2.11 Million USD | -92.56% |
| 2022 | 28.44 Million USD | -28.9% |
| 2021 | 40.01 Million USD | 20.4% |
| 2020 | 33.23 Million USD | -31.33% |
| 2019 | 48.39 Million USD | -10.8% |
| 2018 | 54.26 Million USD | 39.66% |
| 2017 | 38.85 Million USD | 16.91% |
| 2016 | 33.15 Million USD | 4.83% |
| 2015 | 30.04 Million USD | 8.99% |
| 2014 | 29.08 Million USD | 3.52% |
| 2013 | 28.09 Million USD | 2.65% |
| 2012 | 27.43 Million USD | -20.72% |
| 2011 | 34.39 Million USD | -17.52% |
| 2010 | 41.86 Million USD | 20.92% |
| 2009 | 35.01 Million USD | 23.89% |
| 2008 | 28.58 Million USD | 29.38% |
| 2007 | 22.03 Million USD | 16.89% |
| 2006 | 18.68 Million USD | 41.34% |
| 2005 | 13.07 Million USD | 34.0% |
| 2004 | 9.76 Million USD | 154.72% |
| 2003 | 3.85 Million USD | 215.98% |
| 2002 | 1.12 Million USD | 153.72% |
| 2001 | -2.26 Million USD | -29.57% |
| 2000 | -1.75 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -2.04 Million USD | -21.55% |
| 2024 Q3 | -504 Thousand USD | -202.52% |
| 2024 Q1 | -450 Thousand USD | 91.06% |
| 2024 Q2 | 1.27 Million USD | 382.67% |
| 2024 FY | - USD | -95.56% |
| 2023 Q1 | 4.24 Million USD | -45.21% |
| 2023 FY | - USD | -92.56% |
| 2023 Q2 | 3.81 Million USD | -9.99% |
| 2023 Q3 | 172 Thousand USD | -95.5% |
| 2023 Q4 | -6.11 Million USD | -3656.98% |
| 2022 Q1 | 6.06 Million USD | -32.77% |
| 2022 FY | - USD | -28.9% |
| 2022 Q2 | 8.78 Million USD | 44.76% |
| 2022 Q4 | 7.74 Million USD | 32.22% |
| 2022 Q3 | 5.85 Million USD | -33.3% |
| 2021 Q2 | 11.07 Million USD | 10.8% |
| 2021 FY | - USD | 20.4% |
| 2021 Q3 | 9.91 Million USD | -10.5% |
| 2021 Q4 | 9.02 Million USD | -9.0% |
| 2021 Q1 | 9.99 Million USD | 10.26% |
| 2020 Q4 | 9.06 Million USD | 6.76% |
| 2020 Q3 | 8.49 Million USD | -5.02% |
| 2020 Q1 | 6.72 Million USD | -19.54% |
| 2020 Q2 | 8.94 Million USD | 32.9% |
| 2020 FY | - USD | -31.33% |
| 2019 Q2 | 13.75 Million USD | -15.68% |
| 2019 Q1 | 16.31 Million USD | 12.19% |
| 2019 FY | - USD | -10.8% |
| 2019 Q4 | 8.36 Million USD | -16.11% |
| 2019 Q3 | 9.96 Million USD | -27.52% |
| 2018 Q2 | 12.77 Million USD | -14.53% |
| 2018 Q1 | 14.94 Million USD | 22.41% |
| 2018 Q4 | 14.54 Million USD | 21.17% |
| 2018 FY | - USD | 39.66% |
| 2018 Q3 | 12 Million USD | -6.07% |
| 2017 Q4 | 12.21 Million USD | 50.53% |
| 2017 Q2 | 7.93 Million USD | -25.1% |
| 2017 Q1 | 10.59 Million USD | 19.23% |
| 2017 FY | - USD | 16.91% |
| 2017 Q3 | 8.11 Million USD | 2.23% |
| 2016 Q4 | 8.88 Million USD | 14.07% |
| 2016 FY | - USD | 4.83% |
| 2016 Q3 | 7.78 Million USD | 7.05% |
| 2016 Q2 | 7.27 Million USD | -21.61% |
| 2016 Q1 | 9.28 Million USD | 16.14% |
| 2015 Q1 | 8 Million USD | 9.42% |
| 2015 Q2 | 7.87 Million USD | -1.55% |
| 2015 Q3 | 7.83 Million USD | -0.58% |
| 2015 Q4 | 7.99 Million USD | 2.06% |
| 2015 FY | - USD | 8.99% |
| 2014 FY | - USD | 3.52% |
| 2014 Q2 | 6.76 Million USD | -12.69% |
| 2014 Q3 | 7.26 Million USD | 7.45% |
| 2014 Q4 | 7.31 Million USD | 0.63% |
| 2014 Q1 | 7.74 Million USD | 2.91% |
| 2013 FY | - USD | 2.65% |
| 2013 Q4 | 7.52 Million USD | 0.84% |
| 2013 Q3 | 7.46 Million USD | 13.51% |
| 2013 Q2 | 6.57 Million USD | 0.66% |
| 2013 Q1 | 6.53 Million USD | -1.64% |
| 2012 Q4 | 6.64 Million USD | 2.77% |
| 2012 Q2 | 6.36 Million USD | -19.54% |
| 2012 FY | - USD | -20.72% |
| 2012 Q3 | 6.46 Million USD | 1.57% |
| 2012 Q1 | 7.9 Million USD | 16.09% |
| 2011 Q4 | 6.81 Million USD | -9.54% |
| 2011 FY | - USD | -17.52% |
| 2011 Q3 | 7.52 Million USD | -6.38% |
| 2011 Q1 | 12.17 Million USD | 20.94% |
| 2011 Q2 | 8.04 Million USD | -33.95% |
| 2010 Q1 | 12.91 Million USD | 43.23% |
| 2010 Q2 | 10.15 Million USD | -21.42% |
| 2010 FY | - USD | 20.92% |
| 2010 Q3 | 8.72 Million USD | -14.11% |
| 2010 Q4 | 10.06 Million USD | 15.44% |
| 2009 Q1 | 9.75 Million USD | 35.87% |
| 2009 Q2 | 8.41 Million USD | -13.78% |
| 2009 Q4 | 9.01 Million USD | 21.47% |
| 2009 FY | - USD | 23.89% |
| 2009 Q3 | 7.42 Million USD | -11.73% |
| 2008 Q4 | 7.18 Million USD | 13.1% |
| 2008 FY | - USD | 29.38% |
| 2008 Q3 | 6.34 Million USD | 5.05% |
| 2008 Q2 | 6.04 Million USD | -27.74% |
| 2008 Q1 | 8.36 Million USD | 47.96% |
| 2007 FY | - USD | 16.89% |
| 2007 Q4 | 5.65 Million USD | 44.98% |
| 2007 Q3 | 3.89 Million USD | -18.66% |
| 2007 Q2 | 4.79 Million USD | -33.85% |
| 2007 Q1 | 7.24 Million USD | 42.12% |
| 2006 Q4 | 5.09 Million USD | 28.21% |
| 2006 Q3 | 3.97 Million USD | -1.49% |
| 2006 Q2 | 4.03 Million USD | -24.69% |
| 2006 Q1 | 5.36 Million USD | 37.43% |
| 2006 FY | - USD | 41.34% |
| 2005 Q2 | 3.01 Million USD | 4.32% |
| 2005 Q1 | 2.88 Million USD | 25.11% |
| 2005 Q3 | 3.27 Million USD | 8.81% |
| 2005 Q4 | 3.9 Million USD | 19.1% |
| 2005 FY | - USD | 34.0% |
| 2004 Q2 | 3.06 Million USD | 34.59% |
| 2004 FY | - USD | 154.72% |
| 2004 Q3 | 2.11 Million USD | -30.94% |
| 2004 Q1 | 2.27 Million USD | 75.99% |
| 2004 Q4 | 2.3 Million USD | 9.12% |
| 2003 FY | - USD | 215.98% |
| 2003 Q1 | 1.37 Million USD | -11.46% |
| 2003 Q4 | 1.29 Million USD | 66.74% |
| 2003 Q2 | 393.86 Thousand USD | -71.31% |
| 2003 Q3 | 791.2 Thousand USD | 97.24% |
| 2002 Q1 | -782.4 Thousand USD | 10.13% |
| 2002 Q4 | 1.31 Million USD | 238.3% |
| 2002 Q3 | 443.76 Thousand USD | 334.33% |
| 2002 Q2 | 146.04 Thousand USD | 67.32% |
| 2002 FY | - USD | 153.72% |
| 2001 Q2 | -273.25 Thousand USD | 72.18% |
| 2001 FY | - USD | -29.57% |
| 2001 Q1 | -984.21 Thousand USD | 26.59% |
| 2001 Q3 | -332.19 Thousand USD | -22.22% |
| 2001 Q4 | -675.58 Thousand USD | -98.64% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | -1.34 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -22.13 Million USD | 98.22% |
| BIMI International Medical Inc. | -15.33 Million USD | 97.431% |
| China Jo-Jo Drugstores, Inc. | 1.22 Million USD | 132.115% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 9.72 Million USD | 104.052% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 9.72 Million USD | 104.052% |
| Leafly Holdings, Inc. | -5.73 Million USD | 93.129% |
| Leafly Holdings, Inc. | -5.73 Million USD | 93.129% |
| LifeMD, Inc. | -8.21 Million USD | 95.203% |
| LifeMD, Inc. | -8.21 Million USD | 95.203% |
| TRxADE HEALTH, Inc. | -13.72 Million USD | 97.128% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.997% |